PhRMA’s Office of Accountability released its second survey of comments received by companies regarding DTC ads, which showed concern among consumers and physicians about the clarity and creative choices of some ads.
PhRMA did not release the comments, but said most concerned the public health benefits of DTC ads and compliance with FDA regulations. Comments on the public health benefits of ads went both ways, with a number of negative comments concerning specific actors used in ads. Substantial numbers of commenters also expressed confusion about details of an ad or about risk information.
From the July 01, 2007 Issue of MM+M - Medical Marketing and Media
